Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | CPT2 | P23786 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HMGCR | P04035 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7900820 | 0.98 | KDM4E (0.52) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL667630 | 0.90 | TSHR (0.50) | KDM4ETSHRHSD17B10MGAMGAA | |
| SCHEMBL14925256 | 0.86 | FFAR1 (0.73) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL29895960 | 0.85 | TSHR (0.65) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL194853 | 0.83 | KDM4E (0.50) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL48109 | 0.82 | KDM4E (0.65) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL30854909 | 0.82 | KDM4E (0.65) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL11026137 | 0.81 | MGAM (0.50) | KDM4ETSHRHSD17B10MGAMGAA | |
| SCHEMBL15944462 | 0.79 | HMGCR (0.68) | KDM4EFFAR1CPT2TDP1HMGCR | |
| SCHEMBL12055303 | 0.79 | TSHR (0.40) | ADRA1ATSHRHSD17B10MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4321408-A | Preparation of 1,3-dibromo-2,2-dimethyl-propane-1,3-dicarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1982-03-23 | — | — | US | claimed |
| EP-3796900-B1 | TRITERPENE AMINE DERIVATIVES | DFH THERAPEUTICS (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250163066-A1 | PROTACs of MALT1 | TEGID THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119730847-A | NRF2 protein degradation agent | 盖尼米德肿瘤学股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119486728-A | Proteolysis targeting chimeric of mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 特吉德治疗公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4482497-A2 | PROTACS OF MALT1 | Tegid Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240203807-A1 | FLUID-INFUSED ENCAPSULATION OF WATER-SENSITIVE MATERIALS WITH REPLENISHABLE, MULTISCALE WATER REPELLENCY | NATIONAL SCIENCE FOUNDATION | 2024-06-20 | — | — | US | disclosed |
| US-4711896-A | ANTIDIABETIC, ANTILIPEMIC AGENTS | EPIS S.A. (CH) | 1987-12-08 | — | — | US | disclosed |
| EP-0206751-A2 | 2-Substituted quinolines, their preparation and use | MERCK FROSST CANADA INC. (CA) | 1986-12-30 | — | — | EP | disclosed |
| EP-0185080-A1 | — | EPIS SA | 1986-06-25 | — | — | EP | disclosed |
| WO-1986000298-A1 | ALPHA-, OMEGA-DICARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND MEDICINES COMPOSED THEREOF | EPIS S.A. (CH) | 1986-01-16 | — | — | WO | disclosed |
| EP-0065706-B1 | PROCESS FOR THE PREPARATION OF 3,3-DIMETHYLGLUTARIC ACID OR ITS ESTERS | LONZA AG (CH) | 1985-01-16 | — | — | EP | disclosed |
| US-4433163-A | Process for the production of 3,3-dimethylglutaric acid or its esters | LONZA LTD. (CH) | 1984-02-21 | — | — | US | disclosed |
| EP-0065706-A1 | Process for the preparation of 3,3-dimethylglutaric acid or its esters | LONZA AG (CH) | 1982-12-01 | — | — | EP | disclosed |
| US-4321408-A | Preparation of 1,3-dibromo-2,2-dimethyl-propane-1,3-dicarboxylic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1982-03-23 | — | — | US | disclosed |
| EP-0021112-A1 | Process for the preparation of derivatives of 1,3-dibromo-2,2-dimethyl-propane-1,3-dicarboxylic acid, as well as the dichloride of 1,3-dibromo-2,2-dimethyl-propane-1,3-dicarboxylic acid and its monoesterchlorides as intermediary products | BAYER AG (DE) | 1981-01-07 | — | — | EP | disclosed |
| EP-0021113-A1 | Process for the preparation of 3,3-dimethyl-cyclopropane-1,2-dicarboxylic acid esters, intermediates therefor and their production | BAYER AG (DE) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163066-A1 | PROTACs of MALT1 | MALT1, BCL3, BCL9 | KDM4E 428/4885FFAR1 3398/4885CPT2 4405/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | KDM4E 1719/4885FFAR1 2705/4885CPT2 348/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | KDM4E 643/4885FFAR1 3138/4885CPT2 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.